title: An anti-CD44 antibody does not enhance engraftment of DLA-identical marrow after low-dose total body irradiation.
abstract: 920 cGy total body irradiation (TBI) is adequate for consistently successful engraftment of marrow from dog leukocyte antigen (DLA)-identical littermates; however, the dose is inadequate to ensure a marrow graft from DLA-nonidentical unrelated donors. Such mismatched grafts are successful only after 1800 cGy, given in three fractions. While anti-T-cell reagents enhance engraftment of DLA-identical littermate marrow after 920 cGy, they fail to be effective in the DLA-nonidentical setting. However, a monoclonal antibody (mAb) to CD44, S5, was found to be very effective in enhancing engraftment of DLA-nonidentical marrow. The current study asked whether mAb S5 was also effective in the setting of DLA-identical littermate transplants. To this purpose, the TBI dose was lowered to 450 cGy, a dose after which 70% of such grafts failed. Four dogs were treated with antibody S5, 0.2 mg/kg on days -7 through -2 (per previously published protocol), given 450 cGy TBI followed by marrow grafts from their DLA-identical littermates. All four dogs rejected their grafts; two of these died from marrow aplasia, and two survived with endogenous marrow recovery. This result was not statistically significantly different from that in 17, historical (n = 5) and concurrent (n = 12), control dogs where 11 of 17 animals rejected. Even if ten experimental animals were transplanted and all six remaining dogs engrafted, the results still would not have been significantly different from control. This result is in contrast to the successful engraftment promoted by pretreatment with antibody S5 of DLA-nonidentical unrelated dogs, consistent with the notion that different host cells are involved in graft rejection in the two disparate histocompatibility settings.
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Sandmaier
authors.forename: R
authors.initials: R
authors.lastname: Storb
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: E B
authors.initials: EB
authors.lastname: Santos
authors.forename: E
authors.initials: E
authors.lastname: Bryant
authors.forename: F G
authors.initials: FG
authors.lastname: Schuening
authors.forename: H J
authors.initials: HJ
authors.lastname: Deeg
authors.forename: K
authors.initials: K
authors.lastname: Seidel
authors.forename: T
authors.initials: T
authors.lastname: Graham
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D004285:Dogs / Q000276:immunology*; D005260:Female; D006082:Graft Enhancement, Immunologic; D006085:Graft Survival / Q000187:drug effects; D018960:Hyaluronan Receptors / Q000502:physiology*; D008297:Male; D018598:Minisatellite Repeats; D011828:Radiation Chimera; D011829:Radiation Dosage; D014184:Transplantation, Homologous / Q000276:immunology; D014916:Whole-Body Irradiation / Q000009:adverse effects*
chemical_list: D000911:Antibodies, Monoclonal; D018960:Hyaluronan Receptors